Please assess the completion status of the following clinical trial:

Trial Title: A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Rheumatoid Arthritis~* Adults: Treatment of active rheumatoid arthritis (RA) in adults when the response to disease-modifying antirhematic drugs (DMARDs), including MTX, has been inadequate~* Children: Treatment of active polyarticular-course chronic active rheumatoid arthritis in children aged 4 to 17 years who have had an inadequate response to, or whom have proved intolerant of, MTX~Psoriatic Arthritis~- Active and progressive psoriatic arthritis (PsA) in adults who do not respond adequately to previous DMARDs~Exclusion Criteria~* Patients to whom Enbrel is contraindicated as per the local labeling~* Patients with known hypersensitivity to Enbrel or any component of the product~* Patients with sepsis or risk of sepsis~* Patients with active infections including chronic or localized infections such as tuberculosis. (Treatment of Enbrel should not be initiated.)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).